Maizel Ari 4

What Happened
Ari Maizel, Chief Commercial Officer of Axsome Therapeutics (AXSM), received a grant of 16,385 restricted stock units (RSUs) on February 26, 2026 (transaction coded as an award, "A"). The RSUs were granted at $0.00 (no cash paid) and represent a contingent right to receive one share of Axsome common stock per RSU when vested. This is an equity compensation award, not an open‑market purchase or sale.

Key Details

• Transaction date: February 26, 2026; filing date: February 27, 2026 (timely under Form 4 rules).
• Award size: 16,385 RSUs; acquisition price reported as $0.00 (derivative award).
• Shares owned after transaction: Not specified in the portion of the filing provided.
• Vesting/delivery: 25% vests on the 1‑year anniversary (Feb 26, 2027); the remaining RSUs vest in three substantially equal annual installments so the RSUs are fully vested by Feb 26, 2030. Vested shares will be delivered upon the earlier of (i) a Change in Control closing, (ii) the reporting person's separation from service (including termination or death/disability), or (iii) seven years from the grant date.
• Transaction code: A = Award/Grant (derivative); no tax‑withholding or net share settlement noted in the provided footnotes.

Context
RSU grants are a common form of executive compensation and are contingent on vesting and settlement conditions. They do not represent immediate sale or purchase activity and typically do not signal a near‑term trade by the insider—shares are only received (and become tradable) after vesting and delivery events. This filing reports the grant itself and is informational about compensation, not an immediate market transaction.